OSH vs. RXDX, UHS, RDY, RGEN, NBIX, HSIC, INSP, DVA, KRTX, and MASI
Should you be buying Oak Street Health stock or one of its competitors? The main competitors of Oak Street Health include Prometheus Biosciences (RXDX), Universal Health Services (UHS), Dr. Reddy's Laboratories (RDY), Repligen (RGEN), Neurocrine Biosciences (NBIX), Henry Schein (HSIC), Inspire Medical Systems (INSP), DaVita (DVA), Karuna Therapeutics (KRTX), and Masimo (MASI). These companies are all part of the "medical" sector.
Oak Street Health vs.
Oak Street Health (NYSE:OSH) and Prometheus Biosciences (NASDAQ:RXDX) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation, community ranking and media sentiment.
Prometheus Biosciences received 267 more outperform votes than Oak Street Health when rated by MarketBeat users. Likewise, 70.64% of users gave Prometheus Biosciences an outperform vote while only 50.00% of users gave Oak Street Health an outperform vote.
In the previous week, Prometheus Biosciences had 1 more articles in the media than Oak Street Health. MarketBeat recorded 2 mentions for Prometheus Biosciences and 1 mentions for Oak Street Health. Prometheus Biosciences' average media sentiment score of 1.03 beat Oak Street Health's score of 0.00 indicating that Prometheus Biosciences is being referred to more favorably in the news media.
92.0% of Oak Street Health shares are owned by institutional investors. Comparatively, 78.3% of Prometheus Biosciences shares are owned by institutional investors. 11.6% of Oak Street Health shares are owned by insiders. Comparatively, 3.4% of Prometheus Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Oak Street Health currently has a consensus price target of $33.27, suggesting a potential downside of 14.70%. Prometheus Biosciences has a consensus price target of $153.36, suggesting a potential downside of 22.87%. Given Oak Street Health's higher probable upside, equities analysts clearly believe Oak Street Health is more favorable than Prometheus Biosciences.
Oak Street Health has a net margin of -23.57% compared to Prometheus Biosciences' net margin of -3,768.76%. Oak Street Health's return on equity of 0.00% beat Prometheus Biosciences' return on equity.
Oak Street Health has a beta of 2.23, indicating that its stock price is 123% more volatile than the S&P 500. Comparatively, Prometheus Biosciences has a beta of -0.49, indicating that its stock price is 149% less volatile than the S&P 500.
Prometheus Biosciences has lower revenue, but higher earnings than Oak Street Health. Prometheus Biosciences is trading at a lower price-to-earnings ratio than Oak Street Health, indicating that it is currently the more affordable of the two stocks.
Summary
Oak Street Health beats Prometheus Biosciences on 10 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding OSH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oak Street Health Competitors List
Related Companies and Tools
